Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Catalyst Pharm Inc 355 ALHAMBRA CIRCLE SUITE 801 CORAL GABLES FL 33134 USA

www.catalystpharma.com Employees: 167 P: 305-420-3200

Description:

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.'The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.'Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.

Key Statistics

Overview:

Market Capitalization, $K 2,371,749
Enterprise Value, $K 2,234,109
Shares Outstanding, K 118,115
Annual Sales, $ 398,200 K
Annual Net Income, $ 71,410 K
Last Quarter Sales, $ 122,710 K
Last Quarter Net Income, $ 40,790 K
EBIT, $ 122,110 K
EBITDA, $ 154,990 K
60-Month Beta 0.76
% of Insider Shareholders 11.00%
% of Institutional Shareholders 79.22%
Float, K 105,122
% Float 89.00%
Short Volume Ratio 0.34

Growth:

1-Year Return 60.26%
3-Year Return 233.00%
5-Year Return 282.84%
5-Year Revenue Growth 79,540.00%
5-Year Earnings Growth 654.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.56 on 08/07/24
Next Earnings Date 11/13/24
Earnings Per Share ttm 1.06
EPS Growth vs. Prev Qtr 67.74%
EPS Growth vs. Prev Year 57.58%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CPRX Ratios

Ratio
Price/Earnings ttm 18.61
Price/Earnings forward 10.94
Price/Earnings to Growth 3.17
Return-on-Equity % 27.77%
Return-on-Assets % 23.68%
Profit Margin % 17.93%
Debt/Equity 0.00
Price/Sales 5.88
Price/Cash Flow 9.67
Price/Book 3.86
Book Value/Share 5.15
Interest Coverage -1.71
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar